We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lynk

News List

Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002 prnasia
August 12, 2021
Lynk Pharmaceuticals Co., Ltd., an innovative drug development company, announced today that it has administered its triple-kinase inhibitor LNK01002 to the first patient in a phase I clinical trial.
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 prnasia
June 25, 2021
Lynk Pharmaceuticals Co., Ltd. announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (NMPA) for clinical trials of inflammatory bowel disease (IBD).